Loading…
ERNA
Ernexa Therapeutics Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 114082407
$4.57-2.13%Price as of Aug 29, 18:49 UTC · updated once a day, after the close
Key metrics
- Market cap
- $5.33M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.8x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.41
- ROE
- -320.72%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.56
- 52-week high
- $71.50
- 52-week low
- $3.18
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.05▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $30.00 | $108.75 | $675.00 | $1,207.50 | $31,275.00 | $33,600.00 | $33,000.00 | $29,250.00 | $63,150.00 | $127,500.00 | $120,000.00 | $330,000.00 | $472,500.00 | $157,500.00 | $187,500.00 | $285,000.00 | |
| P/S |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LABTLakewood-Amedex Biotherapeutics Inc. | $2.30 | — | 1.2x | — | -402.83% | $5.45M |
| POASPHAOS TECHNOLOGY HOLDINGS (CAYMAN) Ltd | $0.17 | — | — | — | — | $5.21M |
| CDIOCardio Diagnostics Holdings, Inc. | $1.85 | — | 0.7x | — | -75.44% | $5.48M |
| CVKDCadrenal Therapeutics, Inc. |
About the company
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
- 5
- Cambridge, United States
Company description provided by Yahoo Finance.